The Role of Positron Emission Tomography in the Evaluation of Residual Masses After Chemotherapy for Advanced Stage Seminoma

Journal of Urology

Volumn 179, Issue 3, 2008, Pages 936-940

  Hinz, Stefan ^a   Schrader, Mark ^a   Kempkensteffen, Carsten ^a   Bares, Roland ^b   Brenner, Winfried ^c   Krege, Susanne ^d   Franzius, Christiane ^e   Kliesch, Sabine ^e   Heicappel, Ruediger ^f   Miller, Kurt ^a   de Wit, Maike ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f Department of Urology   (Germany)

Author keywords

local; neoplasm recurrence; positron emission tomography; seminoma; testicular neoplasms

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; FALSE POSITIVE RESULT; HUMAN; MALE; MULTICENTER STUDY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; SEMINOMA;

ADULT; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SEMINOMA; TESTICULAR NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 39149113090     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.10.054     Document Type: Article

References (23)

1. McGlynn K.A., Devesa S.S., Sigurdson A.J., Brown L.M., Tsao L., and Tarone R.E. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 97 (2003) 63
2. Flechon A., Bompas E., Biron P., and Droz J.P. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 168 (2002) 1975
3. Herr H.W., Sheinfeld J., Puc H.S., Heelan R., Bajorin D.F., Mencel P., et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol 157 (1997) 860
4. Mosharafa A.A., Foster R.S., Leibovich B.C., Bihrle R., Johnson C., and Donohue J.P. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?. J Urol 169 (2003) 2126
5. Reske S.N., and Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III," 21 July and 19 September 2000. Eur J Nucl Med 28 (2001) 1707
6. Stephens A.W., Gonin R., Hutchins G.D., and Einhorn L.H. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 14 (1996) 1637
7. De Santis M., Becherer A., Bokemeyer C., Stoiber F., Oechsle K., Sellner F., et al. 2-18Fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 22 (2004) 1034
8. Ganjoo K.N., Chan R.J., Sharma M., and Einhorn L.H. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 17 (1999) 3457
9. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor based staging system for metastatic germ cell cancers. J Clin Oncol 15 (1997) 594
10. Sobin L.H., and Wittekind C. TNM Classification of Malignant Tumors (2002), John Wiley and Sons, New York
11. Kollmannsberger C., Oechsle K., Dohmen B.M., Pfannenberg A., Bares R., Claussen C.D., et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer 94 (2002) 2353
12. Weissbach L., and Boedefeld E.A. Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. J Urol 138 (1987) 77
13. Duchesne G.M., Stenning S.P., Aass N., Mead G.M., Fossa S.D., Oliver R.T., et al. Radiotherapy after chemotherapy for metastatic seminoma-a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 33 (1997) 829
14. Warde P., Gospodarowicz M., Panzarella T., Catton C., Sturgeon J., Moore M., et al. Management of stage II seminoma. J Clin Oncol 16 (1998) 290
15. Hain S.F., O'Doherty M.J., Timothy A.R., Leslie M.D., Harper P.G., and Huddart R.A. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 83 (2000) 863
16. Spermon J.R., De Geus-Oei L.F., Kiemeney L.A., Witjes J.A., and Oyen W.J. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int 89 (2002) 549
17. Karapetis C.S., Strickland A.H., Yip D., Steer C., and Harper P.G. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up. Intern Med J 33 (2003) 427
18. Larson S.M. Cancer or inflammation?. A Holy Grail for nuclear medicine. J Nucl Med 35 (1994) 1653
19. Nuutinen J.M., Leskinen S., Elomaa I., Minn H., Varpula M., Solin O., et al. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. Eur J Cancer 33 (1997) 1234
20. Brudin L.H., Valind S.O., Rhodes C.G., Pantin C.F., Sweatman M., Jones T., et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 21 (1994) 297
21. Rayson D., Burch P.A., and Richardson R.L. Sarcoidosis and testicular carcinoma. Cancer 83 (1998) 337
22. Schmoll H.J., Souchon R., Krege S., Albers P., Beyer J., Kollmannsberger C., et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15 (2004) 1377
23. Fossa S.D., Droz J.P., Stoter G., Kaye S.B., Vermeylen K., and Sylvester R. Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group. Br J Cancer 71 (1995) 619